Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492664 | 0.86 | CNR1 (0.45) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL5487600 | 0.86 | HDAC6 (0.46) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL5489115 | 0.83 | CASR (0.45) | CASRMAPTNTRK1KDM4EALDH1A1 | |
| SCHEMBL5781880 | 0.83 | CASR (0.43) | CASRMAPTNTRK1HSD17B10KDM4E | |
| SCHEMBL5493967 | 0.77 | TP53 (0.51) | MAPTALDH1A1TP53POLBRAB9A | |
| SCHEMBL5487630 | 0.75 | HTT (0.47) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL28941049 | 0.74 | NPC1 (0.53) | MAPTNTRK1HSD17B10KDM4ENPC1 | |
| SCHEMBL4452723 | 0.73 | PDPK1 (0.53) | CASRMAPTNTRK1ALDH1A1NPC1 | |
| SCHEMBL5489392 | 0.71 | MAPT (0.43) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL2654169 | 0.69 | PDPK1 (0.50) | MAPTNTRK1ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | claimed |
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | claimed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | claimed |
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | disclosed |
| US-6809113-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, ATHEROSCLEROSIS, DIABETIC NEPHROPATHY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, MULTIPLE SCLEROSIS, NEPHRITIS, PANCREATITIS, PULMONARY FIBROSIS, PSORIASIS, RESTENOSIS TRANSPLANT REJECTION | TELIK, INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CASR 1049/4885MAPT 2283/4885NTRK1 2006/4885 |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CASR 980/4885MAPT 1663/4885NTRK1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.